Patino Alonso, JenniferCabrera González, Justo EnriqueMerino Gracia, JavierNieta Ortiz, GemaKatati, JoumaBezerra Da Cruz, CarlosMateos Gil, PabloCanales Mayordomo, María ÁngelesLópez Montero, IvánIllescas Martínez, Beatriz MaríaDelgado Vázquez, RafaelMartín León, Nazario2024-02-022024-02-022023Patino‐Alonso, Jennifer, et al. «C 60 ‐based Multivalent Glycoporphyrins Inhibit SARS‐CoV‐2 Specific Interaction with the DC‐SIGN Transmembrane Receptor». Small, vol. 20, n.o 19, mayo de 2024, p. 2307045. https://doi.org/10.1002/smll.202307045.1613-681010.1002/smll.202307045https://hdl.handle.net/20.500.14352/98371Since WHO has declared the COVID-19 outbreak a global pandemic, nearly seven million deaths have been reported. This efficient spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is facilitated by the ability of the spike glycoprotein to bind multiple cell membrane receptors. Although ACE2 is identified as the main receptor for SARS-CoV-2, other receptors could play a role in viral entry. Among others, C-type lectins such as DC-SIGN are identified as efficient trans-receptor for SARS-CoV-2 infection, so the use of glycomimetics to inhibit the infection through the DC-SIGN blockade is an encouraging approach. In this regard, multivalent nanostructures based on glycosylated [60]fullerenes linked to a central porphyrin scaffold have been designed and tested against DC-SIGN-mediated SARS-CoV-2 infection. First results show an outstanding inhibition of the trans-infection up to 90%. In addition, a deeper understanding of nanostructure-receptor binding is achieved through microscopy techniques, high-resolution NMR experiments, Quartz Crystal Microbalance experiments, and molecular dynamic simulations.engC60-based Multivalent Glycoporphyrins Inhibit SARS-CoV-2 Specific Interaction with the DC-SIGN Transmembrane Receptorjournal articlehttps://doi.org/10.1002/smll.202307045open access547Química orgánica (Química)23 Química